Additionally, retinoblastoma (RB) is mutated in 10%–25% of high‐grade astrocytomas, and functionally silenced in another ∼15% through amplification of its antagonist CDK410, 30, 53. Here, RB1 is linked to astrocytoma (excluding glioblastoma).